Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk: a Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease subanalysis

Sebastien Foulquier, Michael Boehm, Roland Schmieder, Peter Sleight, Koon Teo, Salim Yusuf, Helmut Schumacher, Thomas Unger*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

10 Citations (Web of Science)
37 Downloads (Pure)

Abstract

Background:In the Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease, all patients were at high cardiovascular risk, and a substantial proportion were hypertensive. We performed a post-hoc analysis to explore the hypothesis that telmisartan has a differential action in hypertensive vs. nonhypertensive patients.Methods:The primary four-fold endpoint (composite of cardiovascular death, myocardial infarction (MI), stroke, or hospitalization for heart failure), the secondary three-fold endpoint (cardiovascular death, MI, and stroke), the individual components, new onset of left ventricular hypertrophy (LVH), and new onset of albuminuria were analyzed.Results:There was no evidence for a significantly differential treatment effect of telmisartan in hypertensive and nonhypertensive patients for any endpoints, although the occurrence of the secondary three-fold endpoint was significantly lower in the telmisartan group (13.0%) compared with placebo (15.0%, P
Original languageEnglish
Pages (from-to)1334-1341
JournalJournal of Hypertension
Volume32
Issue number6
DOIs
Publication statusPublished - Jun 2014

Keywords

  • angiotensin receptor blocker
  • hypertension
  • myocardial infarction
  • telmisartan

Cite this